Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Zoledronic acid versus pamidronate in the treatment of skeletal metastasesin patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial
Autore:
Rosen, LS; Gordon, D; Kaminski, M; Howell, A; Belch, A; Mackey, J; Apffelstaedt, J; Hussein, M; Coleman, RE; Reitsma, DJ; Seaman, JJ; Chen, BL; Ambros, Y;
Indirizzi:
Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Hematol Oncol, Los Angeles, CA 90095 USA Univ Calif Los Angeles Los Angeles CA USA 90095 Los Angeles, CA 90095 USA US Oncol, San Antonio, TX USA US Oncol San Antonio TX USAUS Oncol, San Antonio, TX USA Amer Med Res Inst, Cumming, GA USA Amer Med Res Inst Cumming GA USAAmer Med Res Inst, Cumming, GA USA Christie Hosp, Manchester, Lancs, England Christie Hosp Manchester Lancs England Hosp, Manchester, Lancs, England Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada Cross Canc Inst Edmonton ABCanada T6G 1Z2 , Edmonton, AB T6G 1Z2, Canada Tygerberg Hosp, Cape Town, South Africa Tygerberg Hosp Cape Town South Africa erg Hosp, Cape Town, South Africa Cleveland Clin, Myeloma Res Program, Cleveland, OH 44106 USA Cleveland Clin Cleveland OH USA 44106 es Program, Cleveland, OH 44106 USA Weston Pk Hosp, Yorkshire Canc Res Dept Clin Oncol, Sheffield, S Yorkshire, England Weston Pk Hosp Sheffield S Yorkshire England field, S Yorkshire, England Novartis Pharmaceut Corp, E Hanover, NJ USA Novartis Pharmaceut Corp E Hanover NJ USA maceut Corp, E Hanover, NJ USA Novartis Pharma As, Basel, Switzerland Novartis Pharma As Basel Switzerland rtis Pharma As, Basel, Switzerland
Titolo Testata:
CANCER JOURNAL
fascicolo: 5, volume: 7, anno: 2001,
pagine: 377 - 387
SICI:
1528-9117(200109/10)7:5<377:ZAVPIT>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
BISPHOSPHONATES INDUCE APOPTOSIS; CELLS IN-VITRO; BONE-RESORPTION; COMPLICATIONS; OSTEOCLASTS; INHIBITION; MARKERS; LINES; EFFICACY; PROTEIN;
Keywords:
bone metastases; bisphosphonate; myeloma; breast cancer; supportive care;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Rosen, LS Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Hematol Oncol, 10945 LeConte Ave,Suite 2333, Los Angeles, CA 90095 USA Univ CalifLos Angeles 10945 LeConte Ave,Suite 2333 Los Angeles CA USA 90095
Citazione:
L.S. Rosen et al., "Zoledronic acid versus pamidronate in the treatment of skeletal metastasesin patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial", CANCER J, 7(5), 2001, pp. 377-387

Abstract

PURPOSEZoledronic acid, a new and more potent bisphosphonate, was compared with pamidronate, the current standard treatment for patients with osteolytic or mixed bone metastases/lesions. PATIENTS AND METHODSA total of 1648 patients with either Durie-Salmon stage III multiple myeloma or advanced breast cancer and at least one bone lesion were randomly assigned to treatment with either 4 or 8 mg of zoledronic acid via 15-minute intravenous infusion or 90 mg of pamidronate via 2-hour Intravenous infusionevery 3 to 4 weeks for 12 months. The primary efficacy endpoint was the proportion of patients experiencing at least one skeletal-related event over 13 months. RESULTSThe proportion of patients with at least one skeletal-related event was similar in all treatment groups. Median time to the first skeletal-related event was approximately 1 year In each treatment group. The skeletal morbidity rate was slightly lower in patients treated with zoledronic acid than in those treated with pamidronate, and zoledronic acid (4 mg) significantly decreased the incidence and event rate for radiation therapy to bone, both overall and in breast cancer patients receiving hormonal therapy. Pain scoresdecreased in all treatment groups in the presence of stable or decreased analgesic use. Zoledronic acid (4 mg) and pamidronate were equally well tolerated; the most common adverse events were bone pain, nausea, fatigue, and fever and < 5% of serious adverse events were related to the study drug. The Incidence of renal impairment among patients treated with 4 mg of zoledronic acid via 15-minute infusion was similar to that among patients treated with pamidronate. CONCLUSIONSZoledronic acid (4 mg) via 15-minute intravenous infusion was as effectiveand well tolerated as 90 mg of pamidronate in the treatment of osteolytic and mixed bone metastases/lesions patients with advanced breast cancer or multiple myeloma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 14:52:56